Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study
Children · 09.02.2026 · 13 (2) · 243
DOI: 10.3390/children13020243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Children, online erschienen am 09.02.2026. Verfasst von Jiantong Du und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pediatric cataracts are a main cause of irreversible vision loss and a significant public health challenge. This study aimed to identify pharmacovigilance signals by analyzing large-scale data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Methods
Using real-world data from FAERS (Q1 2004 to Q3 2025), we investigated associations between medications and pediatric cataracts. Following data standardization, signal detection was performed using multiple disproportionality analyses, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). The time to onset was also evaluated.
Results
Among 690,374 reports for individuals aged 0–17 years, 671 reports involving 232 drugs were reported with cataracts. Disproportionality analysis identified 24 drugs with significant signals, predominantly glucocorticoids (11/24), followed by immunosuppressants, monoclonal antibodies, cystic fibrosis transmembrane conductance regulator (CFTR) modulators, antineoplastic agents, an antiepileptic drug, and a colony-stimulating factor. Difluprednate showed the highest pharmacovigilance signal (ROR: 963.67; 95% CI: 316.27–2936.31; n = 4). Notably, CFTR modulators exhibited striking signals: ivacaftor (ROR: 30.75; 95% CI: 18.06–52.37; n = 14), elexacaftor-ivacaftor-tezacaftor (ROR: 15.58; 95% CI: 9.86–24.63; n = 19), and ivacaftor-lumacaftor (ROR: 13.2; 95% CI: 7.9–22.07; n = 15).
Conclusions
This study provides a comprehensive large-scale pharmacovigilance profile of drug-induced pediatric cataracts, identifying agents with high-risk pharmacovigilance signals and underscoring the need for proactive ocular monitoring. These findings can inform clinical decision making and prevention strategies and guide future mechanistic research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Peking University First Hospital, Beijing 100034, China.
Zitieren
APA
Du, J., Xing, C., Zhang, Z., & Ma, Z. (2026). Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study. Children, 13(2), 243. https://doi.org/10.3390/children13020243
Vancouver
Du J, Xing C, Zhang Z, Ma Z. Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study. Children. 2026;13(2):243. doi:10.3390/children13020243
BibTeX
@article{Du2026,
author = {Du, Jiantong and Xing, Chen and Zhang, Zhiyue and Ma, Zonghui},
title = {Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study},
journal = {Children},
year = {2026},
volume = {13},
number = {2},
pages = {243},
doi = {10.3390/children13020243}
}
EUVIMED